EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

PAVmed Inc (PAVM) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of PAVmed Inc $3.02, price $2.87, upside +5.2%, quality 24 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US70387R1068

PI PAVmed Inc logo Thin data Sep 27, 2026

PAVmed Inc

PAVM · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $3.02 · Fairly valued (+5.2%)
!Quality 24/100
!Weak Growth (revenue 3y −42.7 %/yr)
!Low debt · negative free cash flow
!Mixed vs. peers (3/6)
!Narrow moat 3/100
!Evidence only low, so the estimate is less certain
Watch PAVmed Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$3,642 $2.70 Fair Value $3.02 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $2.70 – $3,642 · fair‑value band $2.26 – $3.11 · the $2.87 price screens below the $3.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow PAVmed in your weekly email

Every Wednesday you see whether PAVmed is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States.

Show more

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Stock analysis

PAVmed Inc (PAVM) currently trades at $2.87, while our model-based Fair Value estimate is $3.02, so the stock looks roughly fairly valued today (gap 5.0%).

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of $3.18 per share, and 4 of the 9 models we run sit above the $2.87 price.

Bear case: the Earnings-Based group reads lowest at $0.4700, and 5 of the 9 models stay below the price. Evidence for this calculation is low.

Scenario range: $2.26 (bear) to $3.11 (bull), the price of $2.87 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

PAVmed Inc reported revenue of $71.0K in FY2025 versus $500K in FY2021, a compound −38.6%/yr. Reported net income was $401K in FY2025.

Key figures

Market cap $36.4M · EPS (TTM) $−56.53 · Return on equity −67.2% · Return on assets (EBIT) −128% · Operating margin −36,523% · Revenue (TTM) $85.0K · Revenue growth (YoY) +175% · Free cash flow −$5.2B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 83% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 5%, PAVM screens richer than that median.

Fair Value models

Bear $2.26 Fair Value $3.02 Bull $3.11
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings $136.49 $186.36 $275.85 76
Residual Income $3.24 $3.08 $2.98 71
Graham-Dodd $0.3800 $0.4700 $0.5200 67
All 9 models by family
DCF Models
Owner Earnings $136.49 $186.36 $275.85 76
Earnings-Based
Graham-Dodd $0.3800 $0.4700 $0.5200 67
Multiples
P/E Multiple $0.9200 $1.23 $1.54 63
P/S Multiple $0.0300 $0.0300 $0.0400 58
P/B Multiple $0.7100 $0.9500 $1.19 55
EV/EBITDA $122.19 $162.86 $203.54 67
Asset-Based
NCAV (Graham) $2.37 $3.18 $4.74 54
Economic Profit
Residual Income $3.24 $3.08 $2.98 71
Growth Earnings
Growth-Adj P/E $0.6500 $0.9300 $1.21 67

Open the full fair value analysis →

Notify me when PAVM reaches fair value

Put PAVM on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 24/100

Of which business quality 28 · Market factors (momentum, volatility) 14

Profitability 29
Margins and returns on capital today
Quality Growth 0
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 49
Balance sheet, leverage, solvency risk
Investment 50
Disciplined investing over empire-building
Low Volatility 48
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 50
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−97.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−42.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10,878.6% (2021) → −30,712.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Watch PAVM, get fair value alerts →

Compare PAVmed Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 349 stocks

Beats the industry median on 3/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 24 · Bottom 25%
Fair Value upside +11.9% · Above median
Profitability
Return on assets −31.0% · Bottom 25%
Growth and dividend
Revenue growth 175.0% · Top 25%
Balance sheet
Debt / equity 0.01× · Below median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)40 · sector 9
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)0 · sector 11
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 39

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $98.83 $74.79 −24%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Boston Scientific Corporation BSX $43.65 $48.02 +10%
Edwards Lifesciences Corporation EW $85.19 $81.94 −4%
Siemens Healthineers AG SHL €37.86 €35.19 −7%
DexCom, Inc DXCM $86.68 $95.35 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PAVmed Inc · Fair Value
$3.02 +5%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "PAVmed Inc Fair Value". https://www.fairvalue-calculator.com/stock/PAVM

Frequently asked questions

Is PAVmed Inc (PAVM) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $3.02 versus a price of $2.87, about +5% upside (fairly valued).
What is the fair value of PAVM?
Our model-based fair value for PAVmed Inc is $3.02 (as of Sep 27, 2026), built from audited fundamentals. The current price: $2.87.
What is the quality score of PAVM?
PAVmed Inc has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PAVmed Inc (PAVM)?
Our model-based price target is the fair value of $3.02 (as of Sep 27, 2026) from 9 valuation models. Cautious scenario $2.26, optimistic scenario $3.11. It is a calculation from audited fundamentals, not an analyst target.
What is the PAVmed Inc stock forecast for 2026?
Our models put fair value at $3.02, about +5% upside versus a price of $2.87 (fairly valued). Cautious scenario $2.26, optimistic scenario $3.11. The calculation is refreshed regularly with new filings.
What is the revenue of PAVmed Inc (PAVM)?
PAVmed Inc reported trailing-twelve-month revenue of about $85.0K (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of PAVmed Inc (PAVM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PAVmed Inc it is $3.02 per share (as of Sep 27, 2026), against a price of $2.87. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is PAVmed Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, PAVM trades below its calculated fair value: price $2.87, fair value $3.02, a gap of about +5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PAVM?
No. The price is what the market pays today ($2.87); the fair value is what the company's own numbers justify ($3.02). For PAVmed Inc the two are $0.1500 per share apart. That gap is exactly why we show both numbers side by side.
How much is PAVmed Inc worth?
The market values PAVmed Inc at about $36.4M (market capitalisation, as of Sep 27, 2026). Per share that is $2.87; our models calculate a fair value of $3.02 per share.
What do the bullish and bearish scenarios say about PAVM?
Our models span a range for PAVmed Inc: cautious scenario $2.26, base $3.02, optimistic $3.11 per share (as of Sep 27, 2026, price $2.87). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PAVmed Inc (PAVM)?
Balance-sheet figures for PAVmed Inc (as of Sep 27, 2026): return on equity −67.2%, debt of 0.01 per unit of equity. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is PAVM from its 52-week high?
PAVmed Inc trades at $2.87, about 83% below its 52-week high of $16.66 and 6% above the low of $2.70 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $3.02 is for.
Which stocks are comparable to PAVmed Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PAVmed Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $2.87, calculated fair value $3.02 (+5%), Quality Score 24/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PAVM calculated?
We run PAVmed Inc through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.02, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. PAVmed Inc currently trades 5 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PAVmed Inc (PAVM)?
The closing price on Oct 2, 2026 was $2.87. Our model-based fair value is $3.02, about +5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PAVmed Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of PAVmed Inc

How large is the market capitalisation of PAVmed Inc (PAVM)?
The market capitalisation of PAVmed Inc is $36.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of PAVmed Inc (PAVM)?
Earnings per share at PAVmed Inc are $−56.53. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of PAVmed Inc (PAVM)?
The return on equity (ROE) of PAVmed Inc is −67.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PAVmed Inc (PAVM)?
On an EBIT basis the return on assets of PAVmed Inc is −128% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PAVmed Inc (PAVM)?
The operating margin of PAVmed Inc is −36,523% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PAVmed Inc (PAVM)?
Revenue at PAVmed Inc is growing +175% versus a year earlier (3y avg −42.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does PAVmed Inc (PAVM) generate?
The free cash flow of PAVmed Inc is −$5.2B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does PAVmed Inc (PAVM) carry?
The net debt of PAVmed Inc is $11.8M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch PAVmed Inc in the live analysis

One click puts PAVmed Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.